Edition:
United Kingdom

Celyad SA (CYAD.OQ)

CYAD.OQ on NASDAQ Stock Exchange Global Market

41.25USD
13 Dec 2017
Change (% chg)

$1.22 (+3.05%)
Prev Close
$40.03
Open
$40.05
Day's High
$41.25
Day's Low
$39.86
Volume
482
Avg. Vol
1,325
52-wk High
$64.00
52-wk Low
$17.24

Select another date:

Fri, Nov 17 2017

BRIEF-Celyad ends Q3 with EUR 40 million in cash, confirms previous guidance

* CONFIRMS ITS PREVIOUS GUIDANCE THROUGH TO THE FIRST HALF 2019 Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Celyad reports first complete response in relapsed refractory AML patient in THINK trial ‍​

* REPORTS A FIRST COMPLETE RESPONSE IN A RELAPSED REFRACTORY AML PATIENT IN THE THINK TRIAL ‍​

BRIEF-Celyad SA files for mixed shelf offering of up to $250 mln

* Celyad SA files for mixed shelf offering of up to $250 million - SEC filing ‍​ Source text: [http://bit.ly/2xBg9Sn] Further company coverage:

BRIEF-Celyad H1 operating loss narrows to 13.7 million euros

* H1 OPERATING LOSS EUR 13.7 MILLION VERSUS LOSS OF EUR 17.2 MILLION YEAR AGO

BRIEF-BioLife Solutions executes supply agreement with Celyad for CryoStor

* Biolife Solutions executes supply agreement with Celyad for CryoStor use in natural killer receptor based t-cell (nkr-t) platform targeting solid tumors and blood cancers

BRIEF-Celyad announces initiation of the SHRINK trial

* SHRINK TRIAL IS THIRD CLINICAL TRIAL WITH ITS LEAD PRODUCT CANDIDATE CYAD-01 (CAR-T NKG2D), TARGETING METASTATIC COLORECTAL PATIENTS

BRIEF-Celyad publishes additional pre-clinical data in support of THINK trial ‍​

* PUBLISHES ADDITIONAL PRE-CLINICAL DATA IN SUPPORT OF THINK TRIAL ‍​

Select another date: